
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. has demonstrated significant growth in its Telehealth segment, with an active subscriber base increasing by 14% year-over-year to reach 310,818 by the end of the third quarter of 2025, reflecting heightened consumer demand for virtual healthcare services. The company reported total revenue of $60.2 million, showcasing a 12.7% year-over-year growth, while Telehealth revenue specifically rose by 17.4%, indicating strong performance in this core area. Moreover, with the introduction of new offerings and strategic partnerships, LifeMD is positioned for sustained expansion within the evolving telehealth market, supported by the rising awareness and adoption of remote healthcare solutions.
Bears say
LifeMD Inc reported revenue of $60.2 million for the latest quarter, which represented a 13% year-over-year increase but fell short of consensus expectations of $62.6 million and other guidance estimates. The company's adjusted EBITDA of $5.1 million, up 20% year-over-year, also undershot projected figures, indicating operational challenges amid slowed revenue growth attributed to a reduction in aggressive marketing of compounded products. Additionally, the company has reduced its full-year 2025 revenue guidance for the telehealth segment to $192-193 million, citing competitive pressures from lower-cost alternatives in the market and potential risks related to patient acquisition, profitability, and competition, which collectively contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares